Drug major Eli Lilly will discontinue its animal insulin product "Iletin" after this year and is planning to conduct trials for "inhaled insulin" in the country.
US-based Eli Lilly has planned to continue its focus on innovation-driven products, instead of opening up to opportunities in off-patent generic drugs, being tapped by its larger competitors like GSK and Pfizer.
